LY3405105

LY3405105 is an orally bioavailable, highly selective, covalent inhibitor of cyclin-dependent kinase 7 (CDK7), developed for potential antineoplastic (anticancer) activity. CDK7 is a central regulator of cell cycle progression and gene transcription. By selectively binding to and inhibiting CDK7, LY3405105 disrupts CDK7-mediated signaling pathways, leading to inhibition of cell cycle progression and suppression of transcription in cancer cells. Preclinical studies demonstrated robust antitumor efficacy across multiple tumor types. In clinical trials for advanced solid tumors, the drug showed dose-dependent target occupancy but limited clinical activity and a narrow therapeutic window. As a result, further development was discontinued[1][2][4][6].